font size
Sign in 
Roche’s $5.7 billion hostile bid for the sequencing company Illumina could create a personalized medicine powerhouse capable of not only driving a transformation in the treatment of disease, but its diagnosis as well. Roche has big visions, but the deal has raised some eyebrows. We spoke to Chris Bowe, U.S. Healthcare analyst for Scrip about Roche’s efforts, what it means for personalized medicine, and what some other M&A activity tells us about the industry's changing landscape. Read More
Business Strategy
- Strategic Outsourcing To Buoy European Drug Manufacturers
Shifting market dynamics will free, and then fill, capacity at facilities once kept busy by blockbusters, says consulting firm. Read More
Information Technology
- Kaiser Connects Patients on the Go
New website and free app put lab results, prescription refill requests on mobile phones. Read More
Drug Development
- Novo to Launch Type 1 Diabetes R&D Center
Danish diabetes care giant hopes to leverage basic research to speed drug development. Read More
Conflicts of Interest
- The Physician Payment Sunshine Act: More Darkness Than Light
Desire to uncover conflicts of interest could backfire, sapping innovation. Read More
Public Health
- Gates Gives Global Fund $750 Million Boost
Philanthropist says tough economic times are no excuse for cutting aid to the world’s poorest. Read More
Trials and Tribulations
- Infinity Pharmaceuticals Tanks on Failed Cancer Drug Trial
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
Mergers and Acquisitions
- Big Biotech Fuels M&A Activity
Amgen and Celgene acquisitions add to growing list of biotech buys. Read More
Deals
- Hitting the Target
Verastem goes public in an upsized IPO. Read More
Direct-to-Consumer Advertising
- Can Pharma Cure its Social Anxiety Disorder?
Podcast: January 23, 2012 Read More
Technology
- Proteus Debuts Smart Pill in the United Kingdom
Partnership with pharmacy chain will be the first broad test of market demand for the company’s ingestible sensors. Read More
- The Burrill Report (January 30, 2012): What's Driving Roche's $5.7 Billion Bid for Illumina
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
Now Available
The Burrill Report
February 2012
February 2012
Download a free copy of the January 2012 issue of The Burrill Report. 2011—Year in Review
Click here to download.
Podcast
Can Pharma Cure its Social Anxiety Disorder?
Malcolm Bohm, CEO of LiquidGrids, discusses how pharmaceutical companies can use social media, the regulatory concerns surrounding it, and what it will take for the industry to throw out its old marketing playbook and use the new tools available to it.
Burrill Report Data Center
Finance Scorecard
Filed IPOs
Completed IPOs
PDUFA Dates
Drug Approvals
Burrill Indices
Biggest Movers
By the numbers
Verastem goes public in an upsized IPO
Preclinical biopharma Verastem raised $55 million in an initial public offering, the second life sciences IPO this year.
.jpg)
.gif)
.png){kind=small} |
 |